BIO vs. MRNA: Bio-Rad Laboratories vs. Moderna Stock Comparison

Company Profile

Bio-Rad Laboratories (BIO) and Moderna (MRNA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO is classified in Life Sciences Tools & Services while MRNA is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Moderna (MRNA) is heavily traded at around 21.61M shares per day, whereas Bio-Rad Laboratories (BIO) sees a more moderate 250.78K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Bio-Rad Laboratories (BIO) reports 14.27%, ranking against industry peers normally.

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Bio-Rad Laboratories (BIO) reports 39.45%, ranking against industry peers normally.

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Bio-Rad Laboratories (BIO) reports 11.82%, ranking against industry peers normally.

Profitability Metrics

Growth

Bio-Rad Laboratories (BIO) at 0.65% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Neither Bio-Rad Laboratories (BIO) nor Moderna (MRNA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Bio-Rad Laboratories (BIO) at 3.18 keeps current ratio within its industry’s typical mid-range, while Moderna (MRNA) at 2.30 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for MRNA.

Both Bio-Rad Laboratories (BIO) at 0.18 and Moderna (MRNA) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Bio-Rad Laboratories (BIO) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Bio-Rad Laboratories (BIO) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Bio-Rad Laboratories (BIO) trades at 10.14 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

Bio-Rad Laboratories (BIO) at 3.96 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.

Bio-Rad Laboratories (BIO) at 1.35 looks cheap against book in the lower P/B ratio quartile, while Moderna (MRNA) at 11.58 carries a premium in the upper quartile — a clear price-to-book gap.

Valuation Metrics